CITrate and Evodial for Effective Dialysis (CITED) Study (CITED)
Chronic Kidney Disease
About this trial
This is an interventional treatment trial for Chronic Kidney Disease
Eligibility Criteria
Inclusion Criteria:
- Patients aged over 18 years,
- hemodynamic stability,
- hemoglobin 9 - 12 g/dl.
Exclusion Criteria:
- Any hemostatic disorder favoring either bleeding or clotting,
- anti-vitamin K treatment,
- risk of bleeding according to the criteria of Swartz (12).
Treatment with aspirin, dipyridamole or any drugs likely to interfere with platelet aggregation will be registered carefully, but will not be an exclusion criterion.
All vascular access types (AV-fistula, AV graft, catheter) are allowed. However, only patients with double route vascular access ('bipuncture') will be included in the study.
Sites / Locations
- Universitaire Ziekenhuizen Leuven
- University Hospitals Leuven
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
EVODIAL dialyzer and Selectbag citrate
Regional citrate anticoagulation
Intervention for anticoagulation during dialysis: Combination of Heparin-coated AN69ST membrane (EVODIAL, Gambro-Hospal, Meyzieu, France) and citrate-containing dialysate (Selectbag citrate, Gambro, Lund, Sweden).
Regional citrate anticoagulation, using a hypertonic sterile solution of trisodium citrate dihydrate (1.035 Mol/L, Baxter, Lessines, Belgium), infused into the afferent blood line. Citrate will be infused at a rate of 62.1 mM/h (60 mL/h). The anticoagulant effect of citrate will be neutralized using calcium containing dialysate (Ca 1.50 mmol/L). Dialysate sodium content will be set at 135 mEQ/L, and bicarbonate will be reduced to 25 mEq/L.